Medipharm Labs Corp (LABS) — Cash Flow-to-Debt Ratio
Medipharm Labs Corp (LABS) has a Cash Flow-to-Debt Ratio of -0.09x as of March 2026, meaning its operating cash flow of CA$-778.00K could theoretically repay 0% of its total liabilities (CA$8.52 Million) in one year. See LABS free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Medipharm Labs Corp Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Medipharm Labs Corp across 10 annual periods. For the full cash flow conversion analysis, see LABS cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Medipharm Labs Corp (2016–2025)
Year-by-year debt coverage analysis for Medipharm Labs Corp. Check LABS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.55x | CA$-5.50 Million | CA$9.93 Million | ▼ -20.3% |
| 2024 | -0.46x | CA$-4.86 Million | CA$10.55 Million | ▲ +59.2% |
| 2023 | -1.13x | CA$-12.34 Million | CA$10.93 Million | ▲ +33.3% |
| 2022 | -1.69x | CA$-16.07 Million | CA$9.49 Million | ▼ -18.1% |
| 2021 | -1.43x | CA$-13.21 Million | CA$9.21 Million | ▼ -51.1% |
| 2020 | -0.95x | CA$-37.77 Million | CA$39.82 Million | ▼ -41.2% |
| 2019 | -0.67x | CA$-25.27 Million | CA$37.60 Million | ▲ +10.0% |
| 2018 | -0.75x | CA$-11.11 Million | CA$14.89 Million | ▼ -1235.1% |
| 2017 | 0.07x | CA$166.00K | CA$2.52 Million | ▲ +105.6% |
| 2016 | -1.17x | CA$-54.69K | CA$46.73K | — |